| 2.265 -0.005 (-0.22%) | 07-30 10:28 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.76 |
1-year : | 2.89 |
| Resists | First : | 2.36 |
Second : | 2.48 |
| Pivot price | 2.35 |
|||
| Supports | First : | 2.19 |
Second : | 1.82 |
| MAs | MA(5) : | 2.32 |
MA(20) : | 2.35 |
| MA(100) : | 2.22 |
MA(250) : | 2.13 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 19.3 |
D(3) : | 35.4 |
| RSI | RSI(14): 47 |
|||
| 52-week | High : | 3.19 | Low : | 1.4 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PLX ] has closed above bottom band by 8.2%. Bollinger Bands are 56.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.36 - 2.38 | 2.38 - 2.39 |
| Low: | 2.22 - 2.24 | 2.24 - 2.25 |
| Close: | 2.25 - 2.27 | 2.27 - 2.29 |
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Thu, 30 Jul 2026
PLX|Protalix Biotherapeutics Inc|Price:2.275|Chg%:-0.055 - TradingKey
Wed, 29 Jul 2026
BlackRock (NYSE: BLK) discloses 5.02% ownership in Protalix BioTherapeutics (PLX) - Stock Titan
Wed, 29 Jul 2026
Protalix Biotherapeutics Inc (PLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mon, 27 Jul 2026
Protalix Biotherapeutics Inc (PLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mon, 27 Jul 2026
PLX|Protalix Biotherapeutics Inc|Price:2.275|Chg%:-0.055 - TradingKey
Mon, 27 Jul 2026
Protalix BioTherapeutics Market Sentiment - Benzinga España
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|